Navigation Links
SuperGen in Medical News

SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results

... DUBLIN, Calif., March 2 /PRNewswire-FirstCall/ -- supergen Inc., (Nasdaq: SUPG ), a pharmaceutical company ..., representing approximately 1.5 million shares of supergen common stock. December 2008: The...employees. Conference Call Information supergen will host a conference call to discuss the results...

SuperGen to Announce 2008 Fourth Quarter and Fiscal Year-End Financial Results March 2, 2009

...eplay and conference call replay will be available for 90 days. About supergen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen to Present at BIO CEO & Investor Conference on February 10, 2009

...t www.supergen.com . The webcast will be archived for 90 days. About supergen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008

...armaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For mo...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...aq: OREX ) Repros Therapeutics Inc. (Nasdaq: RPRX ) Sangamo BioSciences Inc. (Nasdaq: SGMO ) Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT ) supergen Inc. (Nasdaq: SUPG ) Transition Therapeutics Inc. (Nasdaq: TTHI ) XOMA Ltd. (Nasdaq: XOMA ) Neuroscience Index (HHN) Drop Neurochem Inc. (...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

... DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de... be a key player in this resistance. Scientists at supergen found that MP470 inhibits these kinases and data p...ignificant unmet clinical need in oncology. About supergen Based in Dublin, Calif.,...

SuperGen Reports 2007 Third Quarter Financial Results

... DUBLIN, Calif., Oct. 29 /PRNewswire-FirstCall/ -- supergen Inc., (Nasdaq: SUPG ), a pharmaceutical company d...itioned to David S. Smith, Ph.D., who joined supergen in March 2007 as Vice President, Regulatory and ...Consumer Healthcare. Conference Call Information supergen will host a conference call to discuss the results...

SuperGen to Announce 2007 Third Quarter Financial Results October 29, 2007

... DUBLIN, Calif., Oct. 22 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de...ference call will be available for 90 days. About supergen Based in Dublin, Calif., SuperGen, Inc. is a phar...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference

... DUBLIN, Calif., Oct. 17 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de... malignancies About supergen Based in Dublin, Calif., SuperGen, Inc. is a phar...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...
SuperGen in Medical Technology

SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia

... DUBLIN, Calif., Dec. 8 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company d...f Pennsylvania support this hypothesis." supergen recently received clearance for a phase I trial wi...ell as several types of leukemias. About supergen Based in Dublin, Calif., SuperGen, Inc. is a ...

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

... DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG), a pharmaceutical company dedi...n was developed through a pivotal Phase 3 study by supergen and partnered to MGI PHARMA, INC. (acquired by Eis...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation

... DUBLIN, Calif., June 16 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de...ner, Manager of Discovery Biology, highlighted how supergen scientists used the company's CLIMB(TM) technology...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

... DUBLIN, Calif., June 13 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models

... DUBLIN, Calif., April 16 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

Data Show SuperGen's MP-470 is Safe in Humans

... DUBLIN, Calif., April 15 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine

...DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de....com . About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the ...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen's MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib

...g erlotinib resistance DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting

... DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor

...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...mation, future events or otherwise. Contacts: supergen Timothy L. Enns S.V.P., Corporate Communications...evelopment (925) 560-0100 tenns@supergen.com supergen Mary M. Vegh Manager, Investor Relations (925) ...
SuperGen in Biological Technology

Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer

Dr. David S. Smith to Head Regulatory and Quality Affairs DUBLIN, Calif., Aug. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malign...

SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor

..., representing approximately 1.5 million shares of supergen common stock. supergen will initiate a Phase I clinical trial to evaluate...as several types of human leukemias. About supergen Based in Dublin, Calif., SuperGen, Inc. is...

SuperGen Reports 2008 Third Quarter Financial Results

...act 571: Modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a small molecule JAK2 inhibitor. Conference Call Information supergen will host a conference call to discuss the 2008 third quarter financial results today at 1:30 p.m. PT / 4:30 p.m. ET. The webcast will be accessible v...

SuperGen to Announce 2008 Third Quarter Financial Results November 4, 2008

... DUBLIN, Calif., Oct. 28 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery ... will be available for 90 days. About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the discovery and development...

SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy

... drug designation for GBM, an often fatal form of brain cancer, can entitle supergen to seven years of market exclusivity. SuperGen's lead product candidate has...e spectrum of cancers, including non-small cell lung cancer. Furthermore, supergen presented four additional posters at the Symposium that reviewed clinical a...

SuperGen Reports 2008 Second Quarter Financial Results

...nager of Discovery Biology, highlighted how supergen scientists used the Company's CLIMB technology to ... scientific forum. Conference Call Information supergen will host a conference call to discuss the results...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008

...armaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For mo...

SuperGen Reports 2008 First Quarter Financial Results

...DUBLIN, Calif., April 28 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ) today reported financial res...red to decitabine. Conference Call Information supergen will host a conference call to discuss the results...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008

...DUBLIN, Calif., April 22 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de...event. About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the ...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008

...DUBLIN, Calif., April 21 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de... days. About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the ...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...
Other Tags
(Date:7/22/2014)... Midland, TX (PRWEB) July 22, 2014 ... of aging often spend a portion of their disposable ... News company is now promoting its best anti aging ... http://cherrynews.com/best-nourishing-eye-serum . , This products guide is now released ... with an Internet connection. Known retailers were selected and ...
(Date:7/22/2014)... Print Audit® has released another significant ... portal. Facilities Manager 3.1.0R includes fixes for issues ... well as numerous new reporting and alerting enhancements. ... is a powerful, easy to use managed print ... automate supplies fulfillment and report service information for ...
(Date:7/22/2014)... City, MO (PRWEB) July 22, 2014 ... Sporting Kansas City vs. Manchester City tickets at Sporting ... will take place on Wednesday, July 23rd. Tickets can ... to game time. Ticket Down can be reached toll ... vs. Manchester City are authentic and covered by Ticket Down's ...
(Date:7/22/2014)... Vitamin C is one of the elements ... to women in the United States. The Cherry News company ... online for women to review at http://cherrynews.com/best-nourishing-eye-serum . , ... one way that beauty product manufacturers are helping to introduce ... are using mixtures of Vitamins C, E and D as ...
(Date:7/22/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and special ... white party dresses to its product category. Additionally, ... available on its website. As a special offer, all customers ... get a discounted rate, up to 54% off. , A ... so its marketing specialist believes the new white party dresses ...
Breaking Medicine News(10 mins):Health News:Best Anti Aging Products Guide Launched for Natural Product Buyers Online at News Portal 2Health News:Print Audit® Releases Facilities Manager 3.1.0R 2Health News:Sporting Kansas City vs. Manchester City Tickets: Ticket Down Has Slashed Ticket Prices for Manchester City vs. Sporting Kansas City on July 23rd 2Health News:Best Vitamin C Serum for Wrinkles List Complied for Women at Consumer News Portal Online 2Health News:Elegant White Party Dresses Now Provided by Distinguished Company iFitDress.com 2
(Date:7/22/2014)... both still images and video of artistic merit ... still images were chosen from more than 250 ... alumni representing more than 25 different University departments. ... submissions. , Zach Donnell, a graduate student in ... noted that the exhibit highlights the interplay between ...
(Date:7/22/2014)... Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2014. Revenue for ... of 53% compared to $4.4 million in the same quarter ... second quarter of 2014 was $1.4 million compared to $0.5 ... revenue and operating income was driven by higher sales of ...
(Date:7/22/2014)... science and engineering professor with an expertise in big ... Foundation grant worth more than $600,000 to develop an ... Heng Huang, an associate professor, will lead the project ... Computer Science and Engineering department. Scientists are compiling and ... number of genes involved in fruit fly development are ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2
Other Contents